Reversible language regression as an adverse effect of topiramate treatment in children.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14745074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Profound language regression developed in three children with epilepsy 4 to 28 weeks after beginning topiramate (TPM). TPM was administered as an adjunctive antiepileptic drug at doses of 2.5 to 6.0 mg/kg/day. Language functions recovered while TPM was being reduced in dose or stopped.
Medical subject headings
- Anticonvulsants
- Fructose
- Language Disorders
- Speech Disorders